Press Room - Sanofi US News
WEB1 day ago · Dr. Fox is a paid advisor to Sanofi for the HERCULES trial. Based on preliminary analysis of the HERCULES study, there was a slight increase in tolebrutinib-treated patients of some adverse events. Liver enzyme elevations (>3xULN) were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group, a …
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB23 hours ago · Sanofi's tolebrutinib drug delays progressive MS by 31% in trial. By Ludwig Burger. September 20, 2024 2:07 PM UTC Updated ago ... Reuters, the news and media division of Thomson Reuters, is the ...
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB22 hours ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
WEB20 hours ago · Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that ...
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study ...
WEB19 hours ago · Sanofi on Friday announced that its investigational BTK inhibitor tolebrutinib delayed the onset of disability progression by 31% in patients with non-relapsing secondary progressive multiple sclerosis.. The results come from the Phase III HERCULES study, a double-blinded randomized trial that compared daily oral tolebrutinib against placebo in terms of confirmed disease progression at six ...
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB22 hours ago · Sanofi revealed the top-line result from HERCULES a few weeks ago, noting that tolebrutinib is the only drug in the oral BTK inhibitor class to have shown an improvement in disability progression ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB18 hours ago · Tolebrutinib also delayed the time to six-month disability progression by 29%. Sanofi is also evaluating tolebrutinib in patients with primary progressive MS in a Phase III PERSUS trial (NCT04458051). Preliminary results from the study are expected in the second half of next year. Earlier this year, the company suspended tolebrutinib’s ...
Press Release: Tolebrutinib demonstrated a 31% delay in time ... - Sanofi
WEB1 day ago · *For participants receiving tolebrutinib. Houman Ashrafian, MD, PhD Head of Research & Development, Sanofi “With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by targeting underlying drivers of the disease. We look forward to discussing these results ...
Press Room - Sanofi US News
WEBFeb 24, 2022 · New preclinical data demonstrated that tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), was the only BTK inhibitor with sufficient central nervous system (CNS) exposure and potency to modulate BTK signaling pathways within the …